Smith & Nephew SNATS, Inc. (NYSE:SNN) Given Consensus Recommendation of “Hold” by Analysts

Smith & Nephew SNATS, Inc. (NYSE:SNN) has been given a consensus recommendation of “Hold” by the six research firms that are presently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $30.9250.

A number of equities research analysts have weighed in on the stock. Canaccord Genuity Group cut their price target on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a report on Monday, May 11th. Sanford C. Bernstein set a $31.85 price target on shares of Smith & Nephew SNATS in a report on Monday, May 11th. Weiss Ratings downgraded shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. The Goldman Sachs Group reissued a “buy” rating on shares of Smith & Nephew SNATS in a report on Monday, May 25th. Finally, Kepler Capital Markets downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th.

Institutional Investors Weigh In On Smith & Nephew SNATS

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Parallel Advisors LLC lifted its holdings in Smith & Nephew SNATS by 20.0% in the 1st quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock valued at $74,000 after acquiring an additional 387 shares during the last quarter. Sunbelt Securities Inc. acquired a new stake in Smith & Nephew SNATS in the 1st quarter valued at about $92,000. Parvin Asset Management LLC lifted its holdings in Smith & Nephew SNATS by 8.5% in the 1st quarter. Parvin Asset Management LLC now owns 36,944 shares of the medical equipment provider’s stock valued at $1,174,000 after acquiring an additional 2,894 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Smith & Nephew SNATS by 33.2% in the 1st quarter. EverSource Wealth Advisors LLC now owns 6,427 shares of the medical equipment provider’s stock valued at $204,000 after acquiring an additional 1,602 shares during the last quarter. Finally, Royal Bank of Canada lifted its holdings in Smith & Nephew SNATS by 6.7% in the 1st quarter. Royal Bank of Canada now owns 337,118 shares of the medical equipment provider’s stock valued at $10,713,000 after acquiring an additional 21,039 shares during the last quarter. 25.64% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew SNATS Stock Performance

SNN stock opened at $30.52 on Friday. The company has a 50-day simple moving average of $31.30 and a 200 day simple moving average of $32.83. Smith & Nephew SNATS has a fifty-two week low of $28.40 and a fifty-two week high of $38.79. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60.

Smith & Nephew SNATS (NYSE:SNN) last posted its quarterly earnings data on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share for the quarter. The company had revenue of $1.60 billion during the quarter. As a group, research analysts predict that Smith & Nephew SNATS will post 2.22 earnings per share for the current year.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.